The BLCAP Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population designed for loss-of-function studies of the BLCAP tumor suppressor gene in a human epithelial context. This product comprises a heterogeneous pool of HeLa cells with targeted disruption of the BLCAP locus, enabling robust interrogation of its roles in apoptosis, cell cycle regulation, and tumor suppression without the need for single-cell cloning. As a polyclonal knockout population, it provides a genetically diverse background that more closely mimics heterogeneous tumor environments, facilitating bulk-population phenotypic and mechanistic analyses.
The host HeLa cell line is an HPV18-positive immortalized epithelial line originally derived from a cervical adenocarcinoma. Its widespread adoption in cancer research stems from its robust growth, ease of genetic manipulation, and well-characterized signaling networks. HeLa cells retain key p53 and apoptotic pathways, making them an appropriate model for examining tumor suppressor mechanisms altered during cervical carcinogenesis.
BLCAP (bladder cancer-associated protein) functions as a tumor suppressor that promotes intrinsic apoptosis by physically interacting with hnRNP K and the translation initiation factor eIF4E. These interactions facilitate mitochondrial outer membrane permeabilization, resulting in cytochrome c release and subsequent activation of caspase-9 and caspase-3. BLCAP activity is transcriptionally regulated by SP1 and is frequently silenced via promoter hypermethylation in cancers. Downstream, BLCAP modulates the expression and activation of p53, BAX, and BCL-2 family proteins, thereby integrating signals that govern cell fate. Its involvement in pre-mRNA splicing further underscores its multifaceted regulatory roles.
In the HeLa cell background, disruption of BLCAP attenuates this apoptotic signaling cascade, leading to enhanced cell survival and proliferation. This knockout model recapitulates a loss-of-function scenario observed in numerous malignancies, including bladder, cervical, hepatocellular, and colorectal cancers, where BLCAP downregulation correlates with poor prognosis. By creating a BLCAP-deficient environment in a p53-proficient, HPV-transformed setting, these cells allow dissection of tumor suppressor pathways independent of viral oncoprotein interference.
Key research applications include investigating apoptosis resistance mechanisms, screening for BLCAP pathway modulators, and evaluating drug responses in a cancer context. Representative experimental approaches include Western blotting and RT-qPCR for expression analysis, Annexin V/MTT assays for cell death and viability, flow cytometry for cell cycle profiling, caspase activity measurements, cytochrome c release immunofluorescence, co-immunoprecipitation for protein interactions, and colony formation or migration/invasion assays for functional phenotypes. For tailored project support, please contact Ascent Research.
